What is the role of the thioredoxin antioxidant complex in relation to HAM/TSP?

References

1. Rafatpanah H, Hosseini RF, Pourseyed SH. The impact of immune response on HTLV-I in HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Iran J Basic Med Sci 2013; 16:235
   [Google Scholar]
2. Futsch N, Prates G, Mahieux R, Casseb J, Dutartre H. Cytokine networks dysregulation during HTLV-1 infection and associated diseases. Viruses 2018; 10:691 [View Article]
   [Google Scholar]
3. Keikha M, Marcondes Fonseca LA, Casseb J. The relevance of HTLV-1-associated myelopathy/tropical spastic paraparesis in Iran: a review study. Rev Clin Med 2019; 6:60–65
   [Google Scholar]
4. Enose-Akahata Y, Vellucci A, Jacobson S. Role of HTLV-1 Tax and HBZ in the pathogenesis of HAM/TSP. Front Microbiol 2017; 8:2563 [View Article]
   [Google Scholar]
5. Fuzii HT, da Silva Dias GA, de Barros RJS, Falcão LFM, Quaresma JAS. Immunopathogenesis of HTLV-1-assoaciated myelopathy/tropical spastic paraparesis (HAM/TSP). Life Sci 2014; 104:9–14 [View Article]
   [Google Scholar]
6. Shomali S, Avval FZ, Boostani R, Jarahi L, Youssefi M. Serum total antioxidant capacity status of HTLV‐1 infected patients. Acta Virol 2015; 59(2:199–203
   [Google Scholar]
7. Matthews JR, Wakasugi N, virelizier J-L, Yodoi J, Hay RT. Thiordoxin regulates the DNA binding activity of NF-χB by reduction of a disulphid bond involving cysteine 62. Nucleic Acids Res 1992; 20:3821–3830 [View Article]
   [Google Scholar]
8. Aguiar CCT, Almeida AB, Araújo PVP, Abreu RN, Chaves EM et al. Oxidative stress and epilepsy: literature review. Oxid Med Cell Longev 2012; 2012:1–12 [View Article]
   [Google Scholar]
9. Yaghoubi N, Youssefi M, Hashemy SI, Rafatpanah H, Mashkani BA et al. Thioredoxin reductase gene expression and activity among human T‐cell lymphotropic virus type 1–infected patients. J Med Virol 2019; 91:865–871
   [Google Scholar]
10. Shomali S, Avval FZ, Boostani R, Jarahi L, Youssefi M. Serum total antioxidant capacity status of HTLV-1 infected patients. Acta Virol 2015; 59:199–203 [View Article]
    [Google Scholar]
11. Benhar M, Shytaj IL, Stamler JS, Savarino A. Dual targeting of the thioredoxin and glutathione systems in cancer and HIV. J Clin Invest 2016; 126:1630–1639 [View Article]
    [Google Scholar]
12. Yodoi J, Uchiyama T. Diseases associated with HTLV-I: virus, IL-2 receptor dysregulation and redox regulation. Immunol Today 1992; 13:405–411 [View Article]
    [Google Scholar]
13. Newman GW, Balcewicz-Sablinska MK, Guarnaccia JR, Remold HG, Silberstein DS. Opposing regulatory effects of thioredoxin and eosinophil cytotoxicity-enhancing factor on the development of human immunodeficiency virus 1. J Exp Med 1994; 180:359–363 [View Article]
    [Google Scholar]
14. Kalantari P, Narayan V, Natarajan SK, Muralidhar K, Gandhi UH et al. Thioredoxin reductase-1 negatively regulates HIV-1 transactivating protein Tat-dependent transcription in human macrophages. J Biol Chem 2008; 283:33183–33190 [View Article]
    [Google Scholar]
15. Mozhgani S-H, Zarei-Ghobadi M, Teymoori-Rad M, Mokhtari-Azad T, Mirzaie M et al. Human T-lymphotropic virus 1 (HTLV-1) pathogenesis: a systems virology study. J Cell Biochem 2018; 119:3968–3979 [View Article]
    [Google Scholar]
16. Mozhgani SH, Piran M, Zarei-Ghobadi M, Jafari M, Mokhtari-Azad T et al. An insight to HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) pathogenesis; evidence from high-throughput data integration and meta-analysis. bioRxiv 2019; 754697:
    [Google Scholar]
17. Kern JC, Kehrer JP. Free radicals and apoptosis: relationships with glutathione, thioredoxin and the Bcl family of proteins. Front Biosci 2005; 10:1727–1738 [View Article][PubMed]
    [Google Scholar]
18. Funasaka Y, Ichihashi M. The effect of ultraviolet B induced adult T cell leukemia-derived Factor/Thioredoxin (ADF/TRX) on survival and growth of human melanocytes. Pigment Cell Res 1997; 10:68–73 [View Article]
    [Google Scholar]
19. Xiao D, Choi S, Johnson DE, Vogel VG, Johnson CS et al. Diallyl trisulfide-induced apoptosis in human prostate cancer cells involves c-Jun N-terminal kinase and extracellular-signal regulated kinase-mediated phosphorylation of Bcl-2. Oncogene 2004; 23:5594–5606 [View Article]
    [Google Scholar]
20. Enose-Akahata Y, Vellucci A, Jacobson S. Role of HTLV-1 Tax and HBZ in the pathogenesis of HAM/TSP. Front Microbiol 2017; 8:2563 [View Article]
    [Google Scholar]
21. Moens B, Decanine D, Menezes SM, Khouri R, Silva-Santos G et al. Ascorbic acid has superior ex vivo antiproliferative, cell death-inducing and immunomodulatory effects over IFN-α in HTLV-1-associated myelopathy. PLoS Negl Trop Dis 2012; 6:e1729 [View Article]
    [Google Scholar]
22. Karbalaei M, Keikha M. What is adult T-cell leukemia pathogenesis? system virology as a solution of this puzzle. Jundishapur J Chronic Dis Care 2019; 8:1–2 [View Article]
    [Google Scholar]
23. Mulloy JC, Kislyakova T, Cereseto A, Casareto L, LoMonico A et al. Human T-cell lymphotropic/leukemia virus type 1 Tax abrogates p53-induced cell cycle arrest and apoptosis through its CREB/ATF functional domain. J Virol 1998; 72:8852–8860
    [Google Scholar]
24. Pise-Masison CA, Mahieux R, Radonovich M, Jiang H, Duvall J et al. Insights into the molecular mechanism of p53 inhibition by HTLV type 1 Tax. AIDS Res Hum Retrov 2000; 16:1669–1675 [View Article]
    [Google Scholar]